20 September 2022 - AVR-RD-04 has previously received orphan drug designation from FDA and EMA. ...
16 September 2022 - Skysona is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys ...
15 September 2022 - Aro Biotherapeutics today announced that the US FDA granted rare paediatric drug designation for ABX1100, an investigational ...
13 September 2022 - Registration now open for 20 September “Early Insights” webinar. ...
8 September 2022 - Designation provides potential for expedited drug development path. ...
30 August 2022 - CADTH recommends against reimbursement and access to potentially life-altering treatment for adult spinal muscular atrophy patients, discounting ...
30 August 2022 - "I have hope again," says Juanita Vernon as the 52 year old tearfully discusses her feelings about ...
24 August 2022 - Maintains orphan drug designation in the EU providing 10 years of market exclusivity. ...
23 August 2022 - GTP-506, a potential single-dose gene editing therapy designed to restore metabolic function in patients suffering with OTC ...
1 August 2022 - It has been suggested that health economists need to improve their methods in order to meet the ...
2 August 2022 - Novartis Korea said Monday that it released Zolgensma, the nation's first gene replacement treatment for spinal ...
1 August 2022 - Adults with debilitating spinal muscular atrophy will for the first time have access to a subsidised ...
22 July 2022 - Positive opinion based on HELIOS-A Phase 3 study. ...
21 July 2022 - Novartis' Zolgensma (onasemnogene abeparvovec), the world's most expensive drug yet to treat spinal muscular atrophy, will ...
19 July 2022 - Independent appraisal committee unanimously determined that evidence is adequate to demonstrate that beti-cel provides a net ...